95亿美元，赛诺菲收购Blueprint，加速罕见免疫疾病领域布局-动脉橙

95亿美元，赛诺菲收购Blueprint，加速罕见免疫疾病领域布局

2025-06-02 BioPharma Dive 等8家媒体报道收购





赛诺菲同意收购总部位于美国的生物制药公司Blueprint Medicines，该公司专注于罕见免疫疾病。此次交易包括Ayvakit/Ayvakyt，这是唯一获批用于治疗晚期和惰性系统性肥大细胞增多症的药物，以及一条前景广阔的免疫学管线。此次收购将增强赛诺菲的免疫学产品组合，并带来elenestinib和BLU-808，这两种药物有望治疗广泛的免疫疾病。赛诺菲将以每股129.00美元的价格支付现金，股权价值约为91亿美元。（摘要由动脉网AI生成）

关联公司

 Sanofi

2025-06-02 Sanofi to acquire Blueprint for up to $9.5B

BioPharma Dive
2025-06-02 Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

CISION
2025-06-02 Sanofi to Acquire Blueprint Medicines to Expand Rare Disease Immunology Portfolio

GeneOnline
2025-06-02 Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

benzinga
2025-06-02 Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

赛诺菲
2025-06-02 Sanofi to Acquire Blueprint Medicines to Strengthen Rare Immunological Disease Portfolio

PHARMA FOCUS ASIA
2025-06-02 Sanofi to Acquire Blueprint Medicines for Over $9 Billion to Expand Immunology Pipeline

GeneOnline
2025-06-02 Sanofi Acquires Blueprint Medicines to Expand Precision Oncology Portfolio

GeneOnline